Login
Illumina NASDAQ: ILMN
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
| Name | Illumina |
| Ticker | ILMN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 298.02 |
| 52W Low/High | 209.20 / 400.74 |
| Market cap | 44 B |
| 1Y Total Return |
-1.65%
Average |
| 1Y Volatility |
44.43%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
Details
| Ticker | ILMN |
| Name | Illumina |
| ISIN | US4523271090 |
| CUSIP | 452327109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 9/17/20
| Close Price | 298.02 |
| 52W Low/High | 209.20 / 400.74 |
| Market cap | 44 B |
| 1Y Total Return |
-1.65%
Average |
| 1Y Volatility |
44.43%
Less Risk |
| Beta | 1.53 |
| PE (trailing) |
63.68
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 20.7% |
| Cash from Op. / Cur. Liabilities | 1.10 |
| Diluted Earnings / Share | 4.68 |
| ROE | 15.6% |
| ROIC | 17.3% |
| Price / Revenue | 13.2 |
| Price / Book | 9.7 |
| Price / CF | 35.8 |
| Current Ratio | 3.8 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.40 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
3,351
|
3,404
|
3,103
|
2,486
|
2,314
|
2,071
|
|
| Gross Profit |
2,357
|
2,344
|
2,137
|
1,647
|
1,619
|
1,470
|
|
| R&D |
623
|
670
|
559
|
531
|
462
|
416
|
|
| EBITDA |
1,108
|
1,312
|
1,100
|
1,171
|
717
|
786
|
|
| Operating Income |
861
|
847
|
856
|
499
|
568
|
650
|
|
| Net Income exc. Extra |
693
|
938
|
648
|
748
|
433
|
486
|
|
| per Share | |||||||
| Diluted avg Shares |
148
|
149
|
148
|
147
|
148
|
149
|
|
| EPS exc. Extra |
4.68
|
6.30
|
4.40
|
5.02
|
2.92
|
3.27
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
7,248
|
6,973
|
5,851
|
4,858
|
3,985
|
3,703
|
|
| Cash, Eq & Invt ShortTerm |
3,268
|
3,173
|
2,512
|
1,893
|
1,425
|
1,510
|
|
| Total Current Assets |
4,194
|
4,156
|
3,337
|
2,643
|
2,143
|
2,238
|
|
| Total Non-Current Assets |
3,054
|
2,817
|
2,514
|
2,215
|
1,842
|
1,465
|
|
| Intangibles |
1,050
|
986
|
1,036
|
967
|
1,044
|
1,013
|
|
| Total Liabilities |
2,685
|
2,641
|
2,500
|
2,143
|
1,845
|
1,909
|
|
| Total Current Liabilities |
1,115
|
612
|
1,217
|
682
|
582
|
725
|
|
| Long Term Debt |
1,570
|
2,029
|
1,283
|
1,461
|
1,264
|
1,184
|
|
| Shareholder equity |
4,563
|
4,332
|
3,257
|
2,715
|
2,056
|
1,794
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,231
|
933
|
1,079
|
784
|
889
|
524
|
|
| Depreciation |
182
|
191
|
164
|
150
|
133
|
117
|
|
| Cash from Investing |
-777
|
-221
|
-937
|
-317
|
190
|
-674
|
|
| Capex |
185
|
232
|
327
|
302
|
186
|
177
|
|
| Cash from Financing |
-622
|
-112
|
-17
|
-198
|
-720
|
71
|
|
| Stock Issued |
-528
|
-210
|
-88
|
-199
|
-283
|
15
|
|
| Debt (LT) Issued |
0
|
183
|
-5
|
8
|
-306
|
-1,254
|
|
| Free Cash Flow |
1,341
|
134
|
876
|
490
|
141
|
131
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
20.7%
|
27.6%
|
20.9%
|
29.8%
|
18.8%
|
23.5%
|
|
| NCFO / Op.Income |
143.0%
|
110.2%
|
126.1%
|
157.1%
|
156.5%
|
80.6%
|
|
| Current Ratio |
3.8
|
6.8
|
2.7
|
3.9
|
3.7
|
3.1
|
|
| Financial Leverage D/E |
0.40
|
0.42
|
0.41
|
0.43
|
0.50
|
0.73
|
|
| Return on Capital Avg |
17.3%
|
25.2%
|
22.5%
|
21.2%
|
19.7%
|
17.7%
|
|
| Return on Shareholder Equity |
15.6%
|
24.7%
|
21.7%
|
31.1%
|
22.6%
|
33.8%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available